This company seems to have little drive to commercialise its research. Its just a big tit for some Dunedin scientists to maintain their lifestyle. I wont hold my breath regarding the projected revenues in a year's time
Printable View
This company seems to have little drive to commercialise its research. Its just a big tit for some Dunedin scientists to maintain their lifestyle. I wont hold my breath regarding the projected revenues in a year's time
You maybe right but they are not the only ones look around they are a few, funnily enough they are quite a few around Dunedin.
I notice that in the recent capital raising Peter Masfen raised his shareholding to 12% and the ACC have purchased a 5% stake.The ACC stake is small bananas in the grand scheme of things but interesting given the state of the listed biotechs at the moment.
I was surprised to see ACC popping up at this point in time...
ACC seem to own virtually everything on the NZX...
....anyway, could be an okay time to own PEB if they were to actually meet their timeframes for completion of the bladder cancer assay clinical trial in the next 6 months (with first revenues expected "soon" after). Full year report due soon and will see how they are progressing.
Web-site is a disappointment with no 2007 report or interim report available there - given they are supposed to be going to the "electronically available" option, this seems a little remiss.
...something I posted on another forum a few months ago in regard to the fariness of the $12m market cap relative to market prospects...
Quote:
Actually, also of interest in this regard is the progress of Matritech who were the major US producer of the Bladderchek test. Matritech was expecting FY07 revenues of around $US15m, coming largely from this business. However, the company continued to report quarterly losses and the assets were recently sold to Inverness Medical Innovations for $US36m. Matritech has since filed for dissolution. The sale and dissolution was expected to realise $US10 - $US12m for shareholders.
How does the PEB product differ from what Matritech did?
My understanding is that the PEB product contains a prognostic as well as diagnostic aspect. But I am not entirely sure. I'm also guessing it is a more expensive test. Not an expert in these things.
Of course PEB also have the colo-rectal and gastric tests in pipeline plus early stage products and IP.
Thanks for the points of difference... :)
I have finally been able to lay my eyes on the annual report, via the companies office web-site where it has now been lodged.
Last year, I recall seeing the notice advising that they would now be not issuing paper copies of the report except where requested and the report would be available on-line. That seemed fine until I received the "shareholder password" in the mail - a few weeks before the report was due to be put on line. Of course, it went into my totally safe filing system :eek: - and was never found again.
Anyway, I am still puzzled as to why a listed company would password protect its annual report on its web-site - I thought listed companies were required to provide potential investors with a copy of their annual report on request anyway? Even if that is not the case, the report is now available (one month later) on the companies web-site, so why the secrecy?